FR13C0013I1 - - Google Patents

Info

Publication number: FR13C0013I1
Authority: FR; France
Prior art keywords: glucagon; analogs; peptide; synthesis; identified
Prior art date: 1996-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-12

Filing date

2013-02-22

Publication date

2013-05-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0013(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-02-22 Application filed filed Critical

2013-05-04 Publication of FR13C0013I1 publication Critical patent/FR13C0013I1/fr

2013-08-16 Application granted granted Critical

2013-08-16 Publication of FR13C0013I2 publication Critical patent/FR13C0013I2/fr

Status Active legal-status Critical Current

Links

102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000008467 tissue growth Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

FR13C0013C 1996-04-12 2013-02-22 Analogues de peptide 2 du type glucagon Active FR13C0013I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63127396A	1996-04-12	1996-04-12
PCT/CA1997/000252 WO1997039031A1 (fr)	1996-04-12	1997-04-11	Analogues de peptide 2 du type glucagon

Publications (2)

Publication Number	Publication Date
FR13C0013I1 true FR13C0013I1 (fr)	2013-05-04
FR13C0013I2 FR13C0013I2 (fr)	2013-08-16

Family

ID=24530501

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR13C0013C Active FR13C0013I2 (fr)	1996-04-12	2013-02-22	Analogues de peptide 2 du type glucagon

Country Status (16)

Country	Link
EP (5)	EP0906338B1 (fr)
JP (3)	JP4148994B2 (fr)
CN (1)	CN1268640C (fr)
AT (2)	ATE478892T1 (fr)
AU (1)	AU733857B2 (fr)
BR (1)	BRPI9708566B8 (fr)
CA (1)	CA2251576C (fr)
DE (2)	DE60142885D1 (fr)
DK (2)	DK0906338T3 (fr)
ES (2)	ES2188929T3 (fr)
FR (1)	FR13C0013I2 (fr)
HK (1)	HK1050204B (fr)
LU (1)	LU92153I2 (fr)
NZ (1)	NZ332281A (fr)
PT (2)	PT906338E (fr)
WO (1)	WO1997039031A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
JP4148994B2 (ja)	1996-04-12	2008-09-10	１１４９３３６オンタリオインコーポレイテッド	グルカゴン様ペプチド―２アナログ
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
CA2236519C (fr)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methodes pour ameliorer le fonctionnement du gros intestin
JP4699576B2 (ja) *	1997-05-16	2011-06-15	１１４９３３６オンタリオインコーポレーテッド	胃腸管上部の機能を強化する方法
EP1060192A2 (fr) *	1998-02-27	2000-12-20	Novo Nordisk A/S	Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
AU7421598A (en) *	1998-05-11	1999-11-29	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
DK1326630T3 (da)	2000-09-18	2008-09-15	Sanos Bioscience As	Anvendelse af GLP-2-peptider
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7411039B2 (en)	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
EP1592471B1 (fr)	2003-02-04	2011-03-23	Novo Nordisk A/S	Dispositif d'injection comportant un mecanisme de dosage rotatif
WO2005019262A1 (fr) *	2003-08-21	2005-03-03	Novo Nordisk A/S	Purification de peptides apparentes au glucagon
EP2368579A1 (fr)	2004-01-21	2011-09-28	Novo Nordisk Health Care AG	Conjugaison au moyen de transglutaminase de peptides
CA2585482C (fr)	2004-11-01	2018-01-02	Nps Allelix Corp.	Traitement de patients atteints du syndrome de l'intestin court avec colon en continuite
CA2607150C (fr)	2005-05-04	2014-08-05	Bjarne Due Larsen	Analogues du glp-2 (glucagon-like-peptide-2)
CN100418983C (zh) *	2005-05-11	2008-09-17	中国药科大学	人胰高血糖素相关肽-2类似物
KR101527233B1 (ko) *	2006-11-08	2015-06-08	질랜드 파마 에이/에스	선택적인 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
CN101824087A (zh) *	2009-03-05	2010-09-08	连云港恒邦医药科技有限公司	胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (fr) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 en utilisation pour la récupération intestinale et musculaire
EP2314616A1 (fr) *	2009-10-23	2011-04-27	Ferring B.V.	Agonistes peptidiques de GLP-2
AU2010312655A1 (en) *	2009-10-30	2012-05-03	Glytech, Inc.	Glycosylated form of antigenic GLP-1 analogue
US9782454B2 (en)	2010-04-22	2017-10-10	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
US20130157954A1 (en) *	2010-05-11	2013-06-20	Nps Pharmaceuticals, Inc.	Methods for treatment or prophylaxis of kidney or liver dysfunction
US20140249090A1 (en)	2011-04-01	2014-09-04	Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V.	Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
CN102924589B (zh) *	2011-08-11	2016-08-24	中肽生化有限公司	胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
CA2872315A1 (fr)	2012-05-03	2013-11-07	Zealand Pharma A/S	Analogues du glucagon-like peptide 2 (glp-2)
CN103159848B (zh) *	2013-01-06	2015-11-25	中国人民解放军第四军医大学	人胰高血糖素样肽-2二串体蛋白及其制备方法
US9789164B2 (en)	2013-03-15	2017-10-17	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
EP3526242A1 (fr) *	2016-10-12	2019-08-21	University of Copenhagen	Agonistes doubles peptidiques de gipr et glp2r
EP3551651B1 (fr)	2016-12-09	2024-03-06	Zealand Pharma A/S	Doubles agonistes glp-1/glp-2 acylés
ES2894629T3 (es)	2017-06-16	2022-02-15	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
WO2019086559A1 (fr)	2017-10-31	2019-05-09	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (fr)	2018-07-23	2020-01-30	Zealand Pharma A/S	Utilisations thérapeutiques d'agonistes de glp-2
EP3628682A1 (fr)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations d'analogues glucagon-like-peptide-2 (glp-2)
EP3628683A1 (fr)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations d'analogues de peptide-2 de type glucagon (glp-2)
US20200254065A1 (en)	2019-02-11	2020-08-13	Opko Biologics Ltd.	Long-acting glp-2 analogs
WO2021071837A1 (fr)	2019-10-07	2021-04-15	Kallyope, Inc.	Agonistes de gpr119
BR112022017039A2 (pt)	2020-02-28	2022-11-16	Kallyope Inc	Agonistas de gpr40
US20230110689A1 (en)	2020-03-30	2023-04-13	Zealand Pharma A/S	Agonist combination
JP2024547006A (ja) *	2021-12-17	2024-12-26	バイナンバイオテックエーピーエス	Ｇｉｐｒ及びｇｌｐ－２ｒのペプチド二重アゴニスト

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5186117A (en)	1975-01-27	1976-07-28	Tanabe Seiyaku Co	Johoseibiryushiseizainoseiho
GB1575343A (en)	1977-05-10	1980-09-17	Ici Ltd	Method for preparing liposome compositions containing biologically active compounds
US4529561A (en)	1978-03-24	1985-07-16	The Regents Of The University Of California	Method for producing liposomes in selected size range
GB2046092B (en)	1979-03-05	1983-11-02	Toyama Chemical Co Ltd	Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en)	1982-03-22	1984-06-05	Klaus Gersonde	Method of and arrangement for producing lipid vesicles
US4725442A (en)	1983-06-17	1988-02-16	Haynes Duncan H	Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en)	1984-06-20	1991-04-16	The Liposome Company, Inc.	Extrusion technique for producing unilamellar vesicles
US4921706A (en)	1984-11-20	1990-05-01	Massachusetts Institute Of Technology	Unilamellar lipid vesicles and method for their formation
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US5009956A (en)	1987-02-24	1991-04-23	Univ Minnesota	Phospholipase A2-resistant liposomes
US4927637A (en)	1989-01-17	1990-05-22	Liposome Technology, Inc.	Liposome extrusion method
US4944948A (en)	1989-02-24	1990-07-31	Liposome Technology, Inc.	EGF/Liposome gel composition and method
JP2961045B2 (ja) *	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
CA2137206A1 (fr)	1993-12-09	1995-06-10	John A. Galloway	Peptites insulinotropiques agissant comme le glucagon, compositions et methodes
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
BR9707807A (pt)	1996-03-01	1999-07-27	Novo Nordisk As	Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo
JP4148994B2 (ja)	1996-04-12	2008-09-10	１１４９３３６オンタリオインコーポレイテッド	グルカゴン様ペプチド―２アナログ
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (fr)	2001-02-01	2002-08-29	Drucker Daniel J	Renforcement de l'activite de glp-2

1997
- 1997-04-11 JP JP53660897A patent/JP4148994B2/ja not_active Expired - Lifetime
- 1997-04-11 EP EP97916280A patent/EP0906338B1/fr not_active Expired - Lifetime
- 1997-04-11 CN CNB971953317A patent/CN1268640C/zh not_active Expired - Lifetime
- 1997-04-11 ES ES97916280T patent/ES2188929T3/es not_active Expired - Lifetime
- 1997-04-11 WO PCT/CA1997/000252 patent/WO1997039031A1/fr not_active Ceased
- 1997-04-11 NZ NZ332281A patent/NZ332281A/xx not_active IP Right Cessation
- 1997-04-11 PT PT97916280T patent/PT906338E/pt unknown
- 1997-04-11 DK DK97916280T patent/DK0906338T3/da active
- 1997-04-11 DE DE60142885T patent/DE60142885D1/de not_active Expired - Lifetime
- 1997-04-11 EP EP10163303.0A patent/EP2218734B1/fr not_active Expired - Lifetime
- 1997-04-11 CA CA2251576A patent/CA2251576C/fr not_active Expired - Lifetime
- 1997-04-11 EP EP08154386A patent/EP2009024A1/fr not_active Withdrawn
- 1997-04-11 EP EP01129072A patent/EP1231219B1/fr not_active Expired - Lifetime
- 1997-04-11 EP EP10012937A patent/EP2275438A1/fr not_active Withdrawn
- 1997-04-11 ES ES01129072T patent/ES2351661T3/es not_active Expired - Lifetime
- 1997-04-11 AT AT01129072T patent/ATE478892T1/de active
- 1997-04-11 AU AU25002/97A patent/AU733857B2/en not_active Expired
- 1997-04-11 DK DK01129072.3T patent/DK1231219T3/da active
- 1997-04-11 BR BRPI9708566A patent/BRPI9708566B8/pt active IP Right Grant
- 1997-04-11 AT AT97916280T patent/ATE227309T1/de active
- 1997-04-11 DE DE69716905T patent/DE69716905T2/de not_active Expired - Lifetime
2001
- 2001-12-07 PT PT01129072T patent/PT1231219E/pt unknown
2003
- 2003-02-07 HK HK03100905.1A patent/HK1050204B/en not_active IP Right Cessation
2007
- 2007-04-24 JP JP2007114302A patent/JP4149497B2/ja not_active Expired - Lifetime
2008
- 2008-02-07 JP JP2008027918A patent/JP5019466B2/ja not_active Expired - Lifetime
2013
- 2013-02-19 LU LU92153C patent/LU92153I2/fr unknown
- 2013-02-22 FR FR13C0013C patent/FR13C0013I2/fr active Active

Also Published As

Publication number	Publication date
ES2188929T3 (es)	2003-07-01
BR9708566B1 (pt)	2012-09-04
CN1244872A (zh)	2000-02-16
AU733857B2 (en)	2001-05-31
DE69716905D1 (de)	2002-12-12
CA2251576A1 (fr)	1997-10-23
EP2009024A1 (fr)	2008-12-31
PT1231219E (pt)	2010-11-30
BRPI9708566B8 (pt)	2022-01-18
BRPI9708566A (pt)	2000-01-04
NZ332281A (en)	2000-03-27
EP2275438A1 (fr)	2011-01-19
WO1997039031A1 (fr)	1997-10-23
JP2007204491A (ja)	2007-08-16
JP2000511881A (ja)	2000-09-12
EP0906338B1 (fr)	2002-11-06
JP2008184465A (ja)	2008-08-14
AU2500297A (en)	1997-11-07
CA2251576C (fr)	2012-08-21
CN1268640C (zh)	2006-08-09
ATE478892T1 (de)	2010-09-15
DE60142885D1 (de)	2010-10-07
HK1050204A1 (en)	2003-06-13
DK1231219T3 (da)	2010-12-20
FR13C0013I2 (fr)	2013-08-16
HK1147761A1 (en)	2011-08-19
EP0906338A1 (fr)	1999-04-07
ES2351661T3 (es)	2011-02-09
EP2218734A3 (fr)	2010-10-13
JP4148994B2 (ja)	2008-09-10
EP2218734A2 (fr)	2010-08-18
EP1231219B1 (fr)	2010-08-25
JP5019466B2 (ja)	2012-09-05
JP4149497B2 (ja)	2008-09-10
DK0906338T3 (da)	2003-03-03
HK1033324A1 (en)	2001-08-24
EP1231219A1 (fr)	2002-08-14
LU92153I2 (fr)	2013-04-19
DE69716905T2 (de)	2003-07-24
EP2218734B1 (fr)	2013-06-05
PT906338E (pt)	2003-03-31
ATE227309T1 (de)	2002-11-15
HK1050204B (en)	2011-09-23

Publication	Publication Date	Title
FR13C0013I1 (fr)	2013-05-04
HUT64298A (en)	1993-12-28	Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
AU681198B2 (en)	1997-08-21	Preparation of 3,4,4-trisubstituted-piperidinyl-N- alkylcarboxylates and intermediates
ZA911153B (en)	1991-11-27	Process for the preparation of oxetanones
HUT59591A (en)	1992-06-29	Process for producing solide, oral retarde pharmaceutical compositions
HU902288D0 (en)	1991-07-29	Process for producing new epimers of 1-alpha-hydroxy-d vitamin and their derivatives as well as pharmaceutical preparatives containing these compounds
ZA961074B (en)	1997-02-26	Chiral Methylphenyloxazolidinones.
HUT51485A (en)	1990-05-28	Process for production of immune-hindering, monoquin, especially internuclein-1-hindering medical compositions
AU7880494A (en)	1995-06-01	5-methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T)
EP0287066A3 (en)	1990-02-14	Process for continuous production of octa -2,7-dien-1-ol
AU7084196A (en)	1997-04-01	Process for preparing a 2-chloro-5-chloromethyl-thiazole compound
MX9803672A (es)	1998-09-30	Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2086065T3 (es)	1996-06-16	Preparacion de tetrahidropiridinas sustituidas.
MY106522A (en)	1995-06-30	Arylaminocarbonyl compounds.
AU1343388A (en)	1988-09-14	Iodinated polymers
BG101794A (en)	1998-10-30	Method for the preparation of trihydrate of (2r, 3s)-3-benzoylamino-2-hydroxy-3-phenylpropionate of 4, 10-diacetoxy-2 alpha-benzoyloxy-5 beta, 20-epoxy-1,7 beta -dihydroxy-9-oco-tax-11-en-13 alpha-yl
HUP9901600A3 (en)	1999-11-29	Vitamin d analogues, their use, pharmaceutical compositions containing them, process for their production and process producing intermediates
ATE253902T1 (de)	2003-11-15	Arzneistoffe zur selektiven bekämpfung von tumorgewebe
ES8105711A1 (es)	1981-06-16	Un metodo de preparar derivados de piperidina
HU9203928D0 (en)	1993-03-29	6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them
HU910463D0 (en)	1991-08-28	Process for the production of medical preparation
NZ332245A (en)	2000-03-27	Substituted benzo-oxazolol carboxylic acid derivatives, process for their production and medicaments containing them
GB2257892B (en)	1993-05-19	Process for producing a food, cosmetic or medical product
MD1193F1 (en)	1999-04-30	Method for surgical correction of the large intestine pathologic mobility
ZA911397B (en)	1991-11-27	N-cycloalkylalkylamines,their process of preparation,their use as a medicament and their synthesis intermediates